Top Suppliers:I want be here

  • DC Chemicals Limited
  • China
  • Product Name: MR 409
  • Price: $Inquiry/100mg $Inquiry/250mg $Inquiry/1g
  • Purity: 98.0%
  • Stocking Period: 3 Day
  • Contact: Tony Cao

1445155-39-4

1445155-39-4 structure
1445155-39-4 structure
  • Name: MR 409
  • Chemical Name: MR 409
  • CAS Number: 1445155-39-4
  • Molecular Formula: C153H252N44O43
  • Molecular Weight: 3395.91
  • Catalog: Research Areas Cancer
  • Create Date: 2022-03-28 17:10:38
  • Modify Date: 2024-01-03 14:34:21
  • MR 409 is a selected growth hormone-releasing hormone (GHRH) agonist. MR 409 has remarkable neuroprotective effects through enhancing endogenous neurogenesis in cerebral ischemic mice. MR 409 also inhibits the in vivo growth of lung cancer[1][2][3][4].

Name MR 409
Description MR 409 is a selected growth hormone-releasing hormone (GHRH) agonist. MR 409 has remarkable neuroprotective effects through enhancing endogenous neurogenesis in cerebral ischemic mice. MR 409 also inhibits the in vivo growth of lung cancer[1][2][3][4].
Related Catalog
In Vitro One week post-myocardial infarction (MI), MR 409 (MR-409) significantly reduces plasma levels of IL-2, IL-6, IL-10 and TNF-α compared to placebo[1]. MR 409 (MR-409; 1 μM) suppresses p53 expression in bovine pulmonary arterial endothelial cells (BPAECs)[2]. MR 409 (1 μM) induces the activation of JAK2, STAT3 and ERK1/2[2]. MR 409 (MR-409; 1 and 5 μM) decreases LPS-induced PGE2 and 8-iso-PGF2α levels, in a dose-dependent manner[3]. MR 409 (1 and 5μM) decreases LPS-induced lactate dehydrogenase (LDH) activity and nitrite production, without showing a dose-dependent effect[3]. MR 409 (1 and 5 μM) decreases LPS-induced gene expression of COX-2, NF-κB and iNOS in colon specimens, without a dose-dependent effect[3]. MR 409 (MR-409) can stimulate endogenous neurogenesis and improve the tMCAO-induced loss of neuroplasticity. MR 409 also enhances the proliferation and inhibits apoptosis of neural stem cells treated with oxygen and glucose deprivation-reperfusion[4]. Western Blot Analysis[2] Cell Line: BPAEC Concentration: 1 μM Incubation Time: 24, 48 and 72 hours Result: Significantly suppressed p53 expression levels after 48 and 72 hours of treatment.
In Vivo MR 409 (MR-409) inhibits the in vivo growth of lung cancer xenografted into nude mice[3]. MR 409 (5 μg; s.c. treated daily for 4 weeks) reduces nociceptive response in mice[3]. Animal Model: Adult C57/BL6 male mice (5 weeks old, weight 20-22 g)[3] Dosage: 5 µg Administration: Treated daily by subcutaneous (s.c.) administration of 0.1 mL solution Result: Showed maximal antinociceptive effects at 2 weeks. Sustained a moderate analgesic effect at 4 weeks.
References

[1]. Rosemeire M Kanashiro-Takeuchi, et al. New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor. Oncotarget. 2015;6(12):9728-39.

[2]. Mohammad A Uddin, et al. GHRH antagonists support lung endothelial barrier function. Tissue Barriers. 2019;7(4):1669989.

[3]. Lucia Recinella, et al. Protective effects of growth hormone-releasing hormone analogs in DSS-induced colitis in mice. Sci Rep. 2021 Jan 28;11(1):2530.

[4]. Yueyang Liu, et al. Agonistic analog of growth hormone-releasing hormone promotes neurofunctional recovery and neural regeneration in ischemic stroke. Proc Natl Acad Sci U S A. 2021 Nov 23;118(47):e2109600118.

Molecular Formula C153H252N44O43
Molecular Weight 3395.91